When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Porphyria cutanea tarda

最后审阅: 14 Aug 2025
最后更新: 31 Aug 2022

小结

定义

病史和体格检查

关键诊断因素

  • blistering skin lesions
完整详情

其他诊断因素

  • skin hyperpigmentation
  • hypertrichosis
  • scarring alopecia
  • red urine
完整详情

危险因素

  • male, middle-aged, white people
  • alcohol use
  • smoking
  • estrogen therapy
  • hepatitis C
  • HIV
  • hereditary hemochromatosis gene (HFE) mutation
  • uroporphyrinogen decarboxylase (UROD) mutations
  • exposure to halogenated polycyclic aromatic hydrocarbons
  • reduced levels of antioxidants
  • end-stage renal disease
  • diabetes mellitus
完整详情

诊断性检查

首要检查

  • plasma total porphyrins
  • plasma fluorescence emission
  • urinary total porphyrins
  • erythrocyte total porphyrins
完整详情

需考虑的检查

  • fractionation of plasma porphyrins by high-performance liquid chromatography (HPLC)
  • fractionation of urinary porphyrins by HPLC
  • erythrocyte uroporphyrinogen decarboxylase (UROD) activity
  • fecal porphyrins
  • DNA studies
  • Liver function tests
  • serum ferritin
  • liver biopsy
  • skin biopsy
  • serum HIV enzyme-linked immunosorbent assay
  • serum hepatitis C surface antibodies
  • creatinine
  • BUN
  • hematocrit
  • hemoglobin
完整详情

治疗流程

急症处理

no phlebotomy contraindications

phlebotomy contraindicated or poorly tolerated

持续性治疗

relapse after remission

撰稿人

作者

Gagan Sood, MD

Associate Professor

Department of Medicine and Surgery

Baylor College of Medicine

Houston

TX

利益声明

GS is an author of a number of references cited in this topic.

Karl E. Anderson, MD

Professor

Departments of Preventive Medicine and Community Health and Internal Medicine

University of Texas Medical Branch

Galveston

TX

利益声明

KEA has received grants from the National Institutes of Health, the US Food and Drug Administration, and Alnylam Pharmaceuticals; he is an author of a number of references cited in this topic. KEA has received consulting fees, advisory board fees, and grants to the university from Alnylam Pharmaceuticals; consulting fees, advisory board fees, and grants from Recordati Rare Diseases; and consulting fees and grants from Mitsubishi Tanabe Pharma America.

同行评议者

Robert S. Dawe, MBChB, MRCP(UK), MD(Glasgow)

Consultant Dermatologist

Honorary Clinical Senior Lecturer

Department of Dermatology

Ninewells Hospital & Medical School

Dundee

UK

利益声明

RSD declares that he has no competing interests.

Jeffrey P. Callen, MD

Professor of Medicine (Dermatology)

University of Louisville

Louisville

KY

利益声明

JPC declares that he has no competing interests.

Montgomery Bissell, MD

Professor and Chief

Gastroenterology

University of California

San Francisco

CA

利益声明

MB declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA. 2007 Jan;104:5079-84.全文  摘要

Jalil S, Grady JJ, Lee C, et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010 Mar;8(3):297-302;e1.全文  摘要

Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019 Nov;128(3):271-81. 摘要

Handler NS, Handler MZ, Stephany MP, et al. Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol. 2017 Jun;56(6):e106-17. 摘要

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

内容使用需遵循免责声明